Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone therapy could ease long COVID's mental toll

NCT ID NCT07714889

Symptom relief Sponsor: Toivoa Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests a coach-guided digital therapeutic called Toivoa-004, designed to help adults with Long COVID manage symptoms of anxiety and depression. The program delivers cognitive behavioral therapy through a smartphone app and is built to be accessible for people with disabilities. Researchers will measure how many participants complete at least 75% of the program over 12 weeks and track changes in mood scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a coach-delivered digital therapeutic platform (Toivoa-004) that provides cognitive behavioral therapy content via a smartphone app
What this could lead to
If successful, this could provide an accessible, scalable way to help people with Long COVID manage anxiety and depression symptoms.
What could go wrong
This is a very small early feasibility study (20 people) focused on engagement, not yet on effectiveness. The digital format may not suit everyone, and results may not generalize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Presence of clinically diagnosed Long COVID. 3. Stated willingness to comply with all study procedures and lifestyle considerations, and availability for the duration of the study. 4. Males and females; Age 22 and above. 5. Clinical Diagnosis of Long COVID 6. Willingness to adhere to the study regiment. 7. Access to necessary resources for participating in a technology-based intervention (i.e., Phone, internet access). 8. Able to read and speak English fluently. 9. Resident of the US and living in the US for the duration of the study. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Exclusion Criteria: 1. Self-reported substance use disorder. In the past 12 months (not including tobacco). 2. Self-reported suicide attempts in the past year or elevated suicide risk other than passive ideation (i.e., endorsing items reflecting intent, identifying means, suicide planning, or suicide-related preparations). 3. Currently pregnant or planning to become pregnant during the treatment period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder Depression depressive disorder long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Depression Long COVID

More trials for these conditions

Other studies related to the condition(s) this trial covers.